(SPTM) SPDR Portfolio S&P 1500 - Ratings and Ratios
Equity, Us, Large-Cap, Mid-Cap, Small-Cap
Description: SPTM SPDR Portfolio S&P 1500 October 30, 2025
SPTM seeks to track the S&P 1500 Composite Index, allocating at least 80 % of its assets to the 1,500 stocks that make up the combined S&P 500, MidCap 400, and SmallCap 600, thereby providing exposure across large-, mid-, and small-cap U.S. equities.
Key metrics (as of Q3 2024) show the fund’s expense ratio at 0.03 %, a weighted average market-cap of roughly $120 billion, and a dividend yield near 1.7 %. The ETF’s performance is closely tied to U.S. macro drivers such as the Federal Reserve’s policy stance, corporate earnings growth, and consumer spending trends, with the technology and health-care sectors historically contributing the most to total return.
For a deeper, data-driven assessment of how SPTM fits into a diversified portfolio, you might explore the quantitative analysis tools on ValueRay.
SPTM ETF Overview
| Market Cap in USD | 11,660m |
| Category | Large Blend |
| TER | 0.03% |
| IPO / Inception | 2000-10-04 |
SPTM ETF Ratings
| Growth Rating | 82.6% |
| Fundamental | - |
| Dividend Rating | 54.9% |
| Return 12m vs S&P 500 | -0.96% |
| Analyst Rating | - |
SPTM Dividends
| Dividend Yield 12m | 1.14% |
| Yield on Cost 5y | 2.49% |
| Annual Growth 5y | 6.28% |
| Payout Consistency | 97.3% |
| Payout Ratio | % |
SPTM Growth Ratios
| Growth Correlation 3m | 93.6% |
| Growth Correlation 12m | 65.3% |
| Growth Correlation 5y | 83.5% |
| CAGR 5y | 22.91% |
| CAGR/Max DD 3y (Calmar Ratio) | 1.21 |
| CAGR/Mean DD 3y (Pain Ratio) | 9.93 |
| Sharpe Ratio 12m | 1.52 |
| Alpha | -1.38 |
| Beta | 1.020 |
| Volatility | 11.50% |
| Current Volume | 766.3k |
| Average Volume 20d | 548.6k |
| Stop Loss | 79.8 (-3.1%) |
| Signal | 0.37 |
What is the price of SPTM shares?
Over the past week, the price has changed by +0.52%, over one month by +2.13%, over three months by +7.97% and over the past year by +20.24%.
Is SPDR Portfolio S&P 1500 a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of SPTM is around 87.00 USD . This means that SPTM is currently overvalued and has a potential downside of 5.62%.
Is SPTM a buy, sell or hold?
What are the forecasts/targets for the SPTM price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 98.1 | 19.1% |
SPTM Fundamental Data Overview October 30, 2025
Beta = 1.02
Revenue TTM = 0.0 USD
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 11.66b USD (11.66b + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 11.66b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 11.66b / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 9.77% (E(11.66b)/V(11.66b) * Re(9.77%) + (debt-free company))
Discount Rate = 9.77% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow 0.0)
Additional Sources for SPTM ETF
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle